Hyperglycemia associated with pasireotide: Results from a mechanistic study in healthy volunteers

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 8, 2013, Pages 3446-3453

  Henry, Robert R ^a   Ciaraldi, Theodore P ^a   Armstrong, Debra ^a   Burke, Paivi ^a   Ligueros Saylan, Monica ^b   Mudaliar, Sunder ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; PASIREOTIDE;

ABDOMINAL CRAMP; ADULT; ARTICLE; BURNING SENSATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE PANCREAS FUNCTION TEST; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCAGON BLOOD LEVEL; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; HISTAMINE LIKE SWELLING; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; HYPERGLYCEMIC CLAMP TEST; HYPERINSULINEMIC EUGLYCEMIC CLAMP TEST; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE STINGING; INSULIN RELEASE; INSULIN SENSITIVITY; LIVER; MALE; NAUSEA; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; SWELLING; UPPER RESPIRATORY TRACT INFECTION; VASOVAGAL REACTION; VOMITING;

ADOLESCENT; ADULT; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; SOMATOSTATIN;

EID: 84881316265     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1771     Document Type: Article

References (32)

1. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006;367:1605-1617.
2. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2002;87:3013-3018.
3. Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008;286: 69-74.
4. Oberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010;21(suppl 7):vii72-vii80.
5. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146:707-716.
6. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24:28-47.
7. Greenman Y, Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab. 1994;78:398-403.
8. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab. 1995;80:1386-1392.
9. Panetta R, Patel YC. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci. 1995; 56:333-342.
10. Bronstein MD, Sheppard M, Freda P, et al. Pasireotide LAR is significantly more effective than octreotideLARat providing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, phase III study. Endocr Rev. 2012;33(03-Meeting Abstracts):OR49-3.
11. Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary dependent Cushing's disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94:115-122.
12. Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010; 95:2781-2789.
13. Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012;366: 914-924.
14. Kumar U, Sasi R, Suresh S, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes. 1999;48:77-85.
15. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
16. Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes. 1987;36:914-924.
17. Campbell PJ, Mandarino LJ, Gerich JE. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism. 1988;37:15-21.
18. Fagan SP, Azizzadeh A, Moldovan S, et al. Insulin secretion is inhibited by subtype five somatostatin receptor in the mouse. Surgery. 1998;124:254-258.
19. Hauge-Evans AC, King AJ, Carmignac D, et al. Somatostatin secreted by islet δ-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes. 2009;58:403-411.
20. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157-198.
21. Zambre Y, Ling Z, Chen MC, et al. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol. 1999;57:1159-1164.
22. Elahi D. In praise of the hyperglycemic clamp. A method for assessment of β-cell sensitivity and insulin resistance. Diabetes Care. 1996;19:278-286.
23. Singh V, Brendel MD, Zacharias S, et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab. 2007;92:673-680.
24. Singh V, Grötzinger C, Nowak KW, et al. Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition. Endocrinology. 2007;148:3887-3899.
25. Pivonello R, De Leo M, Vitale P, et al. Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology. 2010; 92(suppl 1):77-81.
26. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009; 30:152-177.
27. Piatti PM, Monti LD, Caumo A, et al. Mediation of the hepatic effects of growth hormone by its lipolytic activity. J Clin Endocrinol Metab. 1999;84:1658-1663.
28. Nielsen S, Moller N, Christiansen JS, Jorgensen JO. Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes. 2001;50:2301-2308.
29. Bramnert M, Segerlantz M, Laurila E, Daugaard JR, Manhem P, Groop L. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J Clin Endocrinol Metab. 2003;88:1455-1463.
30. Tauchmanova L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002;87:4872-4878.
31. Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing's disease: clinical and health-related quality of life aspects. Eur J Endocrinol. 2012;167:311-326.
32. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999;2:29-41.